Hyperfractionated radiotherapy and multi-agent chemotherapy (procarbazine, ACNU and vincristine) for high-grade gliomas: A prospective study

Anticancer Research

Volumn 26, Issue 3 B, 2006, Pages 2457-2462

  Ogawa, Kazuhiko ^a   Yoshii, Yoshihiko ^a   Toita, Takafumi ^a   Saito, Atsushi ^a   Kakinohana, Yasumasa ^a   Iraha, Shiro ^a   Sugimoto, Koichi ^a   Tsuchida, Yukihiro ^a   Tamaki, Wakana ^a   Adachi, Genki ^b   Hyodo, Akio ^a   Murayama, Sadayuki ^a  

^a UNIVERSITY OF THE RYUKYUS   (Japan)

^b Naha City Hospital   (Japan)

Author keywords

ACNU; Glioblastoma; Glioma; Hyperfractionation; Procarbazine; Radiation therapy; Vincristine

Indexed keywords

NIMUSTINE; PROCARBAZINE; VINCRISTINE;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD TOXICITY; BRAIN HEMORRHAGE; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DEMOGRAPHY; DOSE RESPONSE; DRUG EFFICACY; DRUG USE; FEASIBILITY STUDY; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; GLIOBLASTOMA; GLIOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; LEUKOPENIA; MALE; NAUSEA; PRIORITY JOURNAL; PROSPECTIVE STUDY; SURVIVAL TIME; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASTROCYTOMA; COMBINED MODALITY THERAPY; DOSE FRACTIONATION; FEMALE; GLIOMA; HUMANS; MALE; MIDDLE AGED; NIMUSTINE; OLIGODENDROGLIOMA; PROCARBAZINE; PROSPECTIVE STUDIES; SUPRATENTORIAL NEOPLASMS; VINCRISTINE;

EID: 33745550422     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Fine HA: The basis for current treatment recommendations for malignant gliomas. J Neurooncol 20: 111-120, 1994.
2. Laperriere N, Zuraw L and Cairncross G: Radiotherapy for newly diagnosed malignant glioma in adults: a systematic review. Radiother Oncol 64: 259-273, 2002.
3. Kristiansen K, Hagen S, Kollevold T, Torvik A, Holme I, Nesbakken R, Hatlevoll R, Lindgren M, Brun A, Lindgren S, Notter G, Andersen AP and Eigen K: Combined modality therapy of operated astrocytomas grade III and IV. Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: a prospective multicenter trial of the Scandinavian glioblastoma study group. Cancer 47: 649-652, 1981.
4. Walker MD, Alexander E Jr, Hunt WE, MacCarty CS, Mahaley MS Jr, Mealey J Jr, Norrell HA, Owens G, Ransohoff J, Wilson CB, Gehan EA and Strike TA: Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas: a cooperative clinical trial. J Neurosurg 49: 333-343, 1978.
5. Jeremic B, Shibamoto Y, Grujicic D, Milicic B, Stojanovic M, NIkolic N, Dagovic A and Aleksandrovic J: Pre-irradiation carboplatin and etoposide and accelerated hyperfractionated radiation therapy in patients with high-grade astrocytomas: a phase II study. Radiother Oncol 57: 27-33, 1999.
6. Souhami L, Seiferheld W, Brachman D, Podgorsak EB, Werner-Wasik M, Lustig R, Schultz CJ, Sause W, Okunieff P, Buckner J, Zamorano L, Mehta M and Curran WJ: Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: report of Radiation Therapy Oncology Group 93-05 protocol. Int J Radiat Oncol Biol Phys 60: 853-860, 2004.
7. Stupp R, Mason W, van der Bent MJ, Weller M, Fisher B, Taphoorn MJB, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curshmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross G, Eisenhauer E and Mirimanoff RO: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987-996, 2005.
8. Kleinberg L, Grossman SA, Carson K, Lesser G, O'Neill A, Pearlman J, Phillips P, Herman T and Gerber M: Survival of patients with newly diagnosed glioblastoma multiforme treated with RSR13 and radiotherapy: results of a phase II new approaches to Brain Tumor Therapy CNS Consortium Safety and Efficacy Study. J Clin Oncol 20: 3149-3155, 2002.
9. Fallai C and Olmi P: Hyperfractionated and accelerated radiation therapy in central nervous system tumors (malignant gliomas, pediatric tumors, and brain metastases). Radiother Oncol 43: 235-246, 1997.
10. Beck-Bornholdt HP, Dubben HH, Liertz-Petersen C and Willers H: Hyperfractionation: where do we stand? Radiother Oncol 43: 1-21, 1997.
11. Fine HA, Dear KB, Loeffler JS, Black PM and Canellos GP: Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer 71: 2585-2597, 1993.
12. Stewart LA: Chemotherapy in adult high-grade glioma: a systemic review and meta-analysis of individual patient data from 12 randomized trials. Lancet 359: 1011-1018, 2003.
13. Weller M, Muller B, Koch R, Bamberg M and Karuseneck P: Neuro-Oncology Working Group 01 trial of nimustine plus teniposide versus cytarabine chemotherapy in addition to involved-field radiotherapy in the first-line treatment of malignant glioma. J Clin Oncol 17: 3276-3284, 2003.
14. Shibui S: Randomized control trial on malignant brain tumors - activities of the Japan Clinical Oncology Group-Brain Tumor Study Group. Neurol Med Chir (Tokyo) 44: 220-221, 2004.
15. Hegi ME, Diserens AC, Gorlia T, Nicolas de Tribolet MH, Weller M, Kross JM, Hainfellner JA, Mason W, Mariani L, Bromberg JEC, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC and Stupp R: MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352: 997-1003, 2005.
16. 6-methylguanine in human blood leukocyte DNA during exposure to procarbazine and its relationships with dose and repair. Cancer Res 50: 2759-2764, 1990.
17. Brandes AA, Turazzi S, Basso U, Pasetto LM, Guglielmi B, Volpin L, Iuzzolino P, Amista P, Pinna G, Scienza R and Ermani M: A multidrug combination designed for reversing resistance to BCNU in glioblastoma multiforme. Neurology 58: 1759-1764, 2002.
18. 6-alkylguanine-DNA alkyltransferase in rat tissues. Carcinogenesis 15: 1681-1688, 1994.
19. Lassman LP, Pearce GW and Gang J: Sensitivity of intracranial gliomas to vincristine sulphate. Lancet 1: 296-298, 1965.
20. Levin VA, Edwards MS, Wright DC, Seager ML, Schimberg TP, Townsend JJ and Wilson CB: Modified procarbazine, CCNU, and vincristine (PCV 3) combination chemotherapy in the treatment of malignant brain tumors. Cancer Treat Rep 64: 237-244, 1980.
21. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Central Nervous System. IARC press, Lyon, 2000.
22. National Cancer Institute: Reporting Guidelines, Common Toxicity Criteria V2.0 (CTC). http://ctep.cancer.gov/reporting/CTC-3.html
23. Kaplan EL and Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457-81, 1958.
24. Neider C, Andratschke N, Wiedenmann N, Busch R, Grosu AL and Molls M: Radiotherapy for high-grade gliomas: does altered fractionation improve outcome? Strahlenther Onkol 180: 401-407, 2004.
25. Fu KK, Pajak TF, Trotti A, Jones CU, Spencer SA, Phillips TL, Garden AS, Ridge JA, Cooper JS and Ang KK: A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int J Radiat Oncol Biol Phys 48: 7-16, 2000.
26. Nelson DF, Curran WJ Jr, Scott C, Nelson JS, Weinstein AS, Ahmad K, Constine LS, Murray K, Powlis WD, Mohiuddin M and Fischbach J: Hyperfractionated radiation therapy and bischlorethyl nitrosourea in the treatment of malignant glioma - possible advantage observed at 72.0 Gy in 1.2 Gy B.I.D. fractions: report of the Radiation Therapy Oncology Group Protocol 8302. Int J Radiat Oncol Biol Phys 25: 193-207, 1993.
27. Kleinberg L, Grossman SA, Piantadosi S, Zeltzman M and Wharam M: The effects of sequential versus concurrent chemotherapy and radiotherapy on survival and toxicity in patients with newly diagnosed high-grade astrocytoma. Int J Radiat Oncol Biol Phys 44: 535-543, 1999.
28. Choi IS, Lee SH, Kim TY, Bang JS, Paek SH, Kim S, Kim IH, Heo DS, Bang YJ, Kim DG, Jung HW and Kim NY: Phase II study of chemotherapy with ACNU plus cisplatin followed by cranial irradiation in patients with newly diagnosed glioblastoma multiforme. J Neurooncol 60: 171-176, 2002.
29. Watanabe T, Katayama Y, Yoshino A, Fukaya C and Yamamoto T: Human Interferon beta, nimustine hydrochloride, and radiation therapy in the treatment of newly diagnosed malignant astrocytomas. J Neurooncol 72: 57-62, 2005.
30. Balana C, Lopez-Pousa A, Berrocal A, Yaya-Tur R, Herrero A, Garcia JL, Martin-Broto J, Benavides M, Cerda-Nicolas M, Ballester R, Balart J and Capellades J: Phase II study of temozolomide and cisplatin as primary treatment prior to radiotherapy in newly diagnosed glioblastoma multiforme patients with measurable disease. A study of the Spanish Medical Neuro-Oncology Group (GENOM). J Neurooncol 70: 359-369, 2004.
31. Fountzilas G, Karavelis A, Capizzello A, Kalogera-Fountzila A, Karkavelas G, Zamboglou N, Selviaridis P, Foroglou G and Tourkantonis A: Radiation and concomitant weekly administration of paclitaxel in patients with glioblastoma multiforme. A phase II study. J Neurooncol 45:159-165, 1999.
32. Deutsch M, Green SB, Strike TA, Burger PC, Robertson JT, Selker RG, Shapiro WR, Mealey J Jr, Ransohoff J II, Paoletti P. Smith KR Jr, Odom GL, Hunt WE, Young B, Alexander E Jr, Walker MD and Pistenmaa DA: Results of a randomized trial comparing BCNU plus radiotherapy, streptozotocin plus radiotherapy, BCNU plus hyperfractionated radiotherapy, and BCNU following misonidazole plus radiotherapy in the postoperative treatment of malignant glioma. Int J Radiat Oncol Biol Phys 16: 1389-1396, 1989.
33. Jeremic B, Grujicic D, Antunovic V, Djuric L, Stojanovic M and Shibamoto Y: Hyperfractionated radiation therapy (HFX RT) followed by multiagent chemotherapy (CHT) in patients with malignant glioma: a phase II study. Int J Radiat Oncol Biol Phys 30: 1179-1185, 1994.
34. Murray KJ, Nelson DF, Scott C, Fischbach AJ, Porter A, Farnan N and Curran WJ Jr: Quality-adjusted survival analysis of malignant glioma. Patients treated with twice-daily radiation (RT) and carmustine: a report of the Radiation Therapy Oncology Group (RTOG) 83-02. Int J Radiat Oncol Biol Phys 31: 453-459, 1995.
35. Gilbert M, Armstrong T and Meyers C: Issues in assessing and interpreting quality of life in patients with malignant glioma. Semin Oncol 27(3 Suppl 6): 20-26, 2000.